en
E-mail us
Core Leadership Team
Scientific Advisory Board
Best Cdmo Companies

Core Leadership Team

Crystal Pharmatech was founded and led by scientific experts with extensive Large Pharma experience, e.g., Merck, Abbvie, Pfizer, etc. With more than 10 years of experience in R&D and management, the founder and R&D leaders have supported the research for over 200 drug molecules.


Alex M. Chen
Alex M. Chen, Ph.D.
Co-founder, Chairman & CEO
X
Alex M. Chen, Ph.D.
Alex M. Chen, Ph.D.

Co-founder, Chairman & CEO


  • 21 years of pharmaceutical research experience, including 8 years at Merck Research Laboratories and Merck Manufacturing Division. Supported physical characterization, API form evaluation and selection of over 50 compounds at early and late stage of development. Leading inventors of many polymorph patents for marketed drug products, including Januvia, Isentress, etc. Obtained a B.S. in Chemistry from Peking University and a Ph.D. in Chemistry from Rutgers University.


  • Expertise: Solid-state research, solid form screening, chiral resolution by crystallization, and nanoparticle delivery for gene therapy

Robert Wenslow
Robert Wenslow, Ph.D.
Co-founder, VP of Business Development
X
Robert Wenslow, Ph.D.
Robert Wenslow, Ph.D.

Co-founder, VP of Business Development


  • 26 years of experience in pharmaceutical development, including 14 years at Merck with various leadership positions. Headed the API group - Center for Materials Science and Engineering in Merck Manufacturing Division. Established the first analytical research group in Ireland for Merck, while also maintaining direct responsibilities for overseeing the solid-state NMR facility. Obtained a Ph.D. degree in Chemistry from Pennsylvania State University


  • Expertise: Solid-state NMR, drug characterization, crystallization development, IP protection; Expert witness on crystal form patent cases



Eva Deng
Eva Deng
CFO & Secretary of the Board, Head of the CRO BU NJ Site
X
Eva Deng
Eva Deng

CFO & Secretary of the Board, Head of the CRO BU NJ Site


  • With more than 20 years of financial management experience and rich overseas practical experience. Qualified ACCA Member since 2008. Obtained a master's degree in management from Tsinghua University


Shannon Bi
Shannon Bi
COO, Head of the CRO BU SZ Site
X
Shannon Bi
Shannon Bi

COO, Head of the CRO BU SZ Site


  • With over 14 years of experience in business management. Worked as Vice President of Finance at Xiaodu Technology, a subsidiary company of Baidu Group; served as Sr. Investment Director at Baidu Group. Worked for Standard Chartered Group and a couple of other well-known investment corporations in the past. Obtained a Master degree of Business Administration from Renmin University of China



Rositza Petrova
Rositza Petrova, Ph.D.
Executive Director & Head of Small Molecule Division - NJ Site
X
Rositza Petrova, Ph.D.
Rositza Petrova, Ph.D.

Executive Director & Head of Small Molecule Division - NJ Site


  • 15 years of working experience in Merck with various leadership positions including Leader of API Development Support Group - Center for Materials Science and Engineering in Merck Manufacturing Division, and Analytical Project Leader - Merck Animal Health. Obtained Ph.D. in Materials Science, Georgetown University (Studied chiral separation and crystallization in gels under Professor Jennifer Swift, Ph.D.)


  • Expertise: API solid form screening/discovery, crystalline form selection, polymorphism, and chiral separations by crystallization



Jun Xu
Jun Xu, Ph.D.
Head of R&D – CRO Business Unit, China
X
Jun Xu, Ph.D.
Jun Xu, Ph.D.

Head of R&D – CRO Business Unit, China


  • 7 years of solid-state research and pre-formulation development experience. Led a team to support solid-state research and crystallization for more than 200 compounds and supported the IND filing. Obtained a B.E. and a Ph.D. degree in chemistry from Tsinghua University


  • Expertise: API solid-state research, crystallization development, and pre-formulation research



Decheng Ma
Decheng Ma, Ph.D.
CEO - CDMO Business Unit, China
X
Decheng Ma, Ph.D.
Decheng Ma, Ph.D.

CEO - CDMO Business Unit, China


  • 22 years of formulation development and CRO/CDMO/CMO vendor management experience at Merck (US) and MSD (China). Expertise on oral solid formulation development, analytical and clinical supply. Responsible for or supported over 30 new drug development, 5 of which were commercialized. Trained as Chemical Engineer at Lehigh Univ. (Ph.D.) and Tsinghua Univ. (BS)


  • Expertise: Oral solid formulation development, analytical and clinical supply



Feng Li
Feng Li, Ph.D.
CSO - CDMO Business Unit, China
X
Feng Li, Ph.D.
Feng Li, Ph.D.

CSO - CDMO Business Unit, China


  • 21 years of Phase I-III and commercial formulation development experience at Merck (US). Involved in over 50 small molecule NCE drug product development, 15 of which were commercialized. Significant expertise on oral solid dosage, powder mechanics, dry granulation and pediatric formulation. Trained as an engineer (mechanical leaning) at Penn State Univ. (Ph.D.) and China Agricultural Univ. (BE)

 

  • Expertise: Oral solid dosage, preclinical formulation powder mechanics, dry granulation, high shear wet granulation (HSWG) and pediatric formulation


Xiaoxia (Jessica) Chen
Xiaoxia (Jessica) Chen, Ph.D.
CTO - CDMO Business Unit, China
X
Xiaoxia (Jessica) Chen, Ph.D.
Xiaoxia (Jessica) Chen, Ph.D.

CTO - CDMO Business Unit, China


  • 18 years of pre-formulation, formulation (preclinical-III) and process development, regulatory filing and product commercialization experience at Roche, Abbott, Merck, Sunovion and Sage Therapeutics. Involved in over 35 early phase and 7 commercial products development. Skilled in various delivery systems and unit operations. Trained as Chemical Engineer (Ph.D., Univ. of Texas at Austin; BS and MS, Tsinghua University) and Pharmacometrics (MS, Univ. of Maryland at Baltimore)


  • Expertise: Various delivery systems, preclinical formulation, formulation development, manufacturing unit operations and scale up


Yongqiang Li
Yongqiang Li, Ph.D.
CEO - CDMO Business Unit, Canada
X
Yongqiang Li, Ph.D.
Yongqiang Li, Ph.D.

CEO - CDMO Business Unit, Canada


  • 17 years of formulation development and management experience in innovative and generic pharmaceutical industries. Developed more than 30 products for global markets including First-to-Files, NCE, 505 b (2) and First-to-Markets. Ph.D. degree in Pharmaceutics and Drug Delivery from Faculty of Pharmacy, University of Toronto, Canada


  • Expertise: Complex oral delivery systems, solubility/permeability enhancement, peptide delivery, bioequivalence, and alignment of nonclinical and clinical formulations for NCE drugs


Cen Chen
Cen Chen, Ph.D.
Senior Director, Head of EU BD Department
X
Cen Chen, Ph.D.
Cen Chen, Ph.D.

Senior Director, Head of EU BD Department


  • With over 10 years of R&D and BD experience in pharmaceutical area. Previous roles included senior researcher, director and senior director of Crystal Pharmatech, and is currently the Head of the Group-EU Business Development Department. Led the team to carry out solid-state research and CMC services for over 100 global pharmaceutical companies on more than 200 New Chemical Entities (NCEs), and help more than 10 small molecule candidates entering the IND stage. Obtained Ph.D. degrees in Chemistry from Durham University and currently undertake the Executive MBA course at CEIBS


  • Expertise: Deep understanding of solid state research from early discovery to development stages, focusing on the screening and selection of suitable form and phase of drug candidates


Best Cdmo Companies

Scientific Advisory Board

Our scientific advisory Board includes global leaders in drug development covering amorphous dispersions, co-crystals, crystallization, solid forms, formulation and pre-formulation. The role of our board is all encompassing while we search for new scientific areas for internal and external projects.


Dr. Elizabeth Vadas
Dr. Elizabeth Vadas
InSciTech Inc.
X
Dr. Elizabeth Vadas
Dr. Elizabeth Vadas

InSciTech Inc.


  • 22-year experience at Merck Frosst, former head of Department of Pharmaceutical Research and Development, responsible from early compound characterization to formulation and process development of new chemical entities including the supply of clinical trial materials from phase I through phase III and technical transfer to manufacturing


  • Key contributor on formulation development of SINGULAIR® and several other products that lead to worldwide regulatory approval


  • Past president of CSPS, elected Fellow of AAPS and Fellow of CSPS, adjunct professor of pharmaceutics at the University of Montreal


Dr. Russell Outcalt
Dr. Russell Outcalt
R. Outcalt Consulting, LLC
X
Dr. Russell Outcalt
Dr. Russell Outcalt

R. Outcalt Consulting, LLC


  • Pursued Ph.D. in Chemistry from Rutgers University


  • 8 years at Merck in R&D and manufacturing division


  • Supported physical characterization, API phase selection and evaluation of more than 50 compounds in all stages of development


  • Expert in solid-state characterization, polymorphism, co-crystal screening, chiral resolution, and nanoparticle engineering


Prof. Naír Rodríguez-Hornedo
Prof. Naír Rodríguez-Hornedo
University of Michigan
X
Prof. Naír Rodríguez-Hornedo
Prof. Naír Rodríguez-Hornedo

University of Michigan


  • Developed a research program based on molecular-mechanistic approaches, founded on the premise that the concepts of supramolecular chemistry and crystal engineering


  • Serve on the FDA Advisory Committee for Pharmaceutical Sciences


  • Serve on the editorial boards of Crystal Growth and Design, Molecular Pharmaceutics and Journal of Pharmaceutical Sciences


  • Awards include Ebert Prize for the best article published in the Journal of Pharmaceutical Sciences in 2005


Prof. Lian Yu
Prof. Lian Yu
University of Wisconsin
X
Prof. Lian Yu
Prof. Lian Yu

University of Wisconsin


  • Leading researcher on solid-state chemistry


  • Research areas focused on polymorphism, crystallization of organic glasses, and molecular motions in solids.


  • Honors include Elected Fellow of AAPS, Lilly Research Laboratories President's Award, and Invited Visiting Professorship at the University of Manchester, and David Grant Research Achievement Award in Physical Pharmacy from American Association of Pharmaceutical Scientists


Contact Us
bd_global@crystalpharmatech.com +1-609-604-8303
U.S
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
China
Suite B4-101, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, China, 215123
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
bd_global@crystalpharmatech.com +1-609-604-8303